Aug 13, 2020
ANTI-PD-1/CTLA-4 Bi-specific Antibody (AK104) of Akeso Granted FDA Fast Track Designation for Recurrent and Metastatic Cervical Cancer
Aug 12, 2020
KAHR Medical Announces FDA Clearance of IND Application for DSP107, anti-CD47 Candidate for the Treatment of Solid Tumors
Jun 22, 2020
Agenus Cell Therapy and Checkpoint Antibody Combinations Show Curative Preclinical Efficacy at AACR 2020
Jun 22, 2020
BioInvent and Transgene's BT-001 Achieves Outstanding Tumor Cure Rates in Preclinical Models
Jun 18, 2020
Linnaeus Therapeutics Granted U.S. FDA Fast Track Designation for LNS8801 for the Treatment of Patients with Metastatic or Unresectable Melanoma Who Have Progressed on Anti-PD-1/L1 Therapy
Jun 11, 2020
Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology
Jun 10, 2020
Curis Announces FDA Clearance of IND Application for CI-8993, the First-In-Class Monoclonal Anti-VISTA Antibody
Jun 09, 2020
OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO(TM) and KEYTRUDA® Plus Chemotherapy
Jun 02, 2020
Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study
Jun 01, 2020
Innovent Announces the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study
Jun 01, 2020
Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
May 27, 2020
Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort
May 25, 2020
Innovent Announces First Patient Dosed in A Phase 1 Clinical Trial of Anti-TIGIT Monoclonal Antibody in China
May 13, 2020
OncoSec's TAVO(TM) Receives ATMP Certification from European Medicines Agency to Support Marketing Authorization Application in Metastatic Melanoma
May 07, 2020
Agenus First Quarter Results and Update
May 06, 2020
OncoSec's TAVO(TM) in Combination with KEYTRUDA® Demonstrated 41% Overall Response Rate and 36% Complete Response in a Late-Stage Metastatic Melanoma Study Featured in 'Clinical Cancer Research'
Apr 23, 2020
SITC Announces Three Recipients of the 2020 Richard V. Smalley, MD, Memorial Award and Lectureship
Apr 09, 2020
Vigeo Therapeutics Doses First Patients in Expansion Phase of its 1b/2 Study Investigating VT1021 in Patients with CD36 Expressing Cancers
Apr 06, 2020
Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies
Mar 30, 2020
Alphamab Oncology, Simcere and 3D Medicines Announce Partnership to Develop and Commercialize Subcutaneous Injectable anti-PD-L1 Antibody for Oncology Indications in Mainland China